A focused forum where practising physicians deepen IBD knowledge, exchange clinical insights, and stay current with evolving evidence.
Why this SIG, right now
Inflammatory bowel disease presents ongoing clinical challenges that require up-to-date knowledge and peer collaboration across all practice settings.
The IBD treatment landscape continues to grow, making it essential to understand comparative efficacy, sequencing, and safety profiles across available agents.
Treat-to-target strategies and tighter definitions of remission are reshaping how clinicians monitor and adjust therapy over time.
Patients with IBD often carry comorbid conditions and require coordinated care, making cross-specialty communication and shared decision-making central to good outcomes.
Chair's Note
Inflammatory bowel disease management is changing rapidly, with new therapeutic classes and shifting treatment targets demanding continuous learning. This group gives clinicians a structured space to work through that complexity together.
Join Inflammatory Bowel Disease Special Interest Group to read and participate in the discussion board.
Sign In